Shareholder Services

ASX shareholders

Clinuvel maintains its ASX shareholder registry with Computershare. For all enquiries related to your shareholding, contact:

ComputerShare

The Registrar
Computershare Investor Services Pty Limited
GPO Box 2975
Australia
(Aus) 1300 555 159
(International) +61 (0)3 9415 4062

Shareholders are able to access the company's share registry with Computershare online and perform the following tasks:

View Your Security Holdings

  • Account Details
  • Balances
  • Communication Details

Change your Shareholdings Records

Click here to go to the Computershare website.

American Depository Receipts holders

Clinuvel's stock is available as an ADR through the Bank of New York Mellon under the symbol CLVLY.

For all enquiries related to ADR ownership, contact:

BNY Mellon Shareowner Services
P.O. Box 358516
Pittsburgh, PA 15252-8516
USA
(USA) 1888 BNY ADRS or - 1888 269 2377 (toll free)
(International) +1 201 680 6825
Email This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.bnymellon.com/shareowner

Investors' Blog Posts

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight